Surgical Outcomes of Thalamic Tumors in Children: The Importance of Diffusion Tensor Imaging, Neuro-Navigation and Intraoperative Neurophysiological Monitoring

Jun-Hoe Kim1, Ji Hoon Phi1,2, Ji Yeoun Lee1,2,2, Kyung Hyun Kim1,2,4, Sung-Hye Park5, Young Hun Choi6, Byung-Kyu Cho7, Seung-Ki Kim1,2

1Department of Neurosurgery, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea
2Division of Pediatric Neurosurgery, Seoul National University Children’s Hospital, Seoul, Korea
3Departments of Anatomy, Pathology, Seoul National University College of Medicine, Seoul, Korea
4Regional Emergency Medical Center, Seoul National University Hospital, Seoul, Korea
5Division of Pediatric Radiology, Seoul National University Children’s Hospital, Seoul National University College of Medicine, Seoul, Korea
6Department of Neurosurgery, The Armed Forces Capital Hospital, Seongnam, Korea

Background Recently, modern technology such as diffusion tensor imaging (DTI), neuro-navigation and intraoperative neurophysiological monitoring (IOM) have been actively adopted for the treatment of thalamic tumors. We evaluated surgical outcomes and efficacy of the aforementioned technologies for the treatment of pediatric thalamic tumors.

Methods We retrospectively reviewed clinical data from 37 children with thalamic tumors between 2004 and 2017. There were 44 operations (27 tumor resections, 17 biopsies). DTI was employed in 17 cases, neuro-navigation in 23 cases and IOM in 14 cases. All diagnoses were revised according to the 2016 World Health Organization Classification of Tumors of the Central Nervous System. Progression-free survival (PFS) and overall survival (OS) rates were calculated, and relevant prognostic factors were analyzed. The median follow-up duration was 19 months.

Results Fifteen cases were gross total resections (GTR), 6 subtotal resections (STR), and 6 partial resections (PR). Neurological status did not worsen after 22 tumor resections. There were statistically significant differences in terms of the extent of resection between the groups with DTI, neuro-navigation and IOM (n=12, GTR or STR=12) and the group without at least one of the three techniques (n=15, GTR or STR=9, p=0.020). The mean PFS was 87.2±38.0 months, and the mean OS 90.7±36.1 months. The 5-year PFS was 37%, and the 5-year OS 47%. The histological grade (p≤0.001) and adjuvant therapy (done vs. not done, p=0.016) were significantly related to longer PFS. The histological grade (p=0.002) and the extent of removal (GTR/STR vs. PR/biopsy, p=0.047) were significantly related to longer OS.

Conclusion Maximal surgical resection was achieved with acceptable morbidity in children with thalamic tumors by employing DTI, neuro-navigation and IOM. Maximal tumor resection was a relevant clinical factor affecting OS; therefore, it should be considered the initial therapeutic option for pediatric thalamic tumors.

Key Words Thalamic diseases; Diffusion tensor imaging; Neuronavigation; Intraoperative neurophysiological monitoring; Treatment outcome.

INTRODUCTION

Thalamic tumors constitute about 1–5% of pediatric intracranial tumors [1-5]. Gliomas predominate among pathologic diagnoses. The proportion of high-grade lesions is much higher in thalamic tumors than in tumors in other locations of brain
In the past, conservative approaches such as stereotactic biopsy or radiotherapy were preferred for treatment of thalamic tumors rather than radical resection because the thalamus is surrounded by important white matter tracts and the thalamus itself is a crucial structure [7]. However, it has been reported that the efficacy of chemotherapy and survival can be increased by resection of these tumors [8,9]. Currently, with the help of preoperative neuroimaging and intraoperative neurophysiological monitoring (IOM), surgical resection of thalamic tumors has become achievable with acceptable morbidity [2-4,7,10-12].

Because of the rarity of thalamic tumors in children, the surgical outcomes and relevant prognostic factors for this disease are not clearly defined. Furthermore, the role of the aforementioned technologies on outcomes, including the extent of resection and postoperative neurological status, has not been clearly stated. Therefore, we reviewed the records of 37 children with thalamic tumors and evaluated the surgical outcomes and relevant prognostic factors. This study provides up-to-date information regarding the role of diffusion tensor imaging (DTI), neuro-navigation and IOM in the treatment of pediatric thalamic tumors.

MATERIALS AND METHODS

The Institutional Review Boards of Seoul National University Hospital approved the study protocol (H-1610-079-799). We retrospectively reviewed the medical records of 37 children with thalamic tumors treated at the Division of Pediatric Neurosurgery of Seoul National University Children’s Hospital from March 2004 to December 2017. The data include demographics, presenting symptoms, imaging characteristics, tumor extent, histology, treatment received and follow-up. The median follow-up duration was 19 months (range from 1 to 225 months).

We independently reviewed the preoperative and postoperative MRI to determine the epicenter of the tumor, the neighboring structures and the extent of tumor resection. There were 44 operations in our study. Twenty-seven cases were tumor resections, and the other 17 cases were biopsies. DTIs were done before surgery in 17 tumor resections, and these images were reviewed by a pediatric neuroradiologist (Choi Y.H.), particularly for the displacement of the thalamus and the internal capsule. Neuro-navigation was employed in 23 cases, and IOM was used in 14 cases.

The extent of resection was divided into gross total resection (GTR, 100% removal), subtotal resection (STR, 90–99% removal) and partial resection (PR, <90% removal) based on the intraoperative findings and postoperative MRIs. The postoperative neurological outcomes were divided into two groups: “Worsened” and “Not worsened.” Neurological evaluations included mental status and motor grades of extremities. The “Worsened” group had decreased mental status from alert to less than alert or a decreased motor grade to ≤3 from a motor grade of ≥4. Patients not meeting these criteria were included in the “Not worsened” group [13,14]. Pathology specimens were reviewed by a neuropathologist (Park S.H.). All diagnoses were reviewed according to the 2016 World Health Organization (WHO) Classification of Tumors of the Central Nervous System (CNS) [15].

Statistical analysis was performed using the SPSS 19 statistical package (IBM Corp., Armonk, NY, USA). Fisher’s exact test was used for binary of categorical variables. We calculated progression-free survival (PFS) and overall survival (OS) using the Kaplan-Meier method. For comparison of variables in the Kaplan-Meier curves, a log-rank test was used. The level of significance (p) was 0.05 for all the tests.

RESULTS

Clinical features

Thirty-seven patients were enrolled in the study. Age at diagnosis ranged between 1.1 and 21.5 years (median 9.8 years). The male to female ratio was approximately 1:1. The duration of symptoms ranged between 0.2 and 28 weeks (median 2 weeks). Symptoms of increased intracranial pressure (n=20) and hemiparesis (n=8) were the most common presenting symptoms, followed by tremor (n=4), dizziness (n=1), gait disturbance (n=1), and rigidity (n=1). Two patients had MRI because of head trauma, and the tumors were considered incidental lesions.

Neuroimaging

Thirty-one patients had unilateral thalamic tumors, and 6 patients had bilateral thalamic tumors (Table 1). Tumors were only located in the thalamus in 22 patients with unilateral tumor and 5 with bilateral tumors. Tumors extended to the cerebral peduncle and midbrain in 6 patients with unilateral tumor. The tumor extended to the basal ganglia in 1 patient with a unilateral tumor. Tumors extended to the periventricular white matter in 2 patients with unilateral tumors and 1 with a bilateral tumor. Preoperative DTIs were done in 17 tumor

| Extent of tumors   | Laterality       |
|-------------------|-----------------|
|                   | Unilateral | Bilateral | Total |
| Thalamus          | 22         | 5         | 27    |
| Thalamus-peduncle-midbrain | 6           | 0         | 6     |
| Thalamus-basal ganglia | 1          | 0         | 1     |
| Thalamus-PVWM     | 2           | 1         | 3     |
| Total             | 31          | 6         | 37    |

PVWM, periventricular white matter
Surgery of Pediatric Thalamic Tumors

resections. In particular, displacement and involvement of the posterior limb of the internal capsule (PLIC) was evaluated by DTI because it is important to avoid this crucial structure in planning surgical approach in order to avoid postoperative hemiparesis [16]. Eleven cases had displacement of the PLIC (8 anterolateral deviation, 2 lateral deviation and 1 anteromedial deviation) and among them, 3 had PLIC infiltration. The PLIC was not visualized in 3 cases that had heavy destruction of the PLIC by tumor. Three cases had normal position of the PLIC. These data, including the surgical approach planned with DTI findings, are summarized in Table 2.

**Tumor resection**
Forty-four operations were performed for these 37 patients. We performed 17 biopsies and 27 tumor resections. Among the 27 tumor resection cases, 15 cases were GTR, 6 were STR and 6 were PR. Thirteen tumor removals were done via inter-hemispheric transcalslosal approaches, and 14 tumor resections were made via transcortical approaches. When we compared the extent of resection between the group with DTI, neuro-navigation and IOM (n=12) and the group without at least one of the three techniques (n=15), all 12 tumor resection cases in the former group were GTR or STR, and 9 out of 15 tumor resection cases in the latter group were GTR or STR (Fig. 1). The difference was statistically significant (p=0.020).

**Neurological status after tumor resection**
There were 27 tumor resections in 23 patients. In 22 tumor resection cases, neurological status did not worsen after surgery. In 5 tumor resection cases, neurological status worsened after surgery. When we analyzed the differences in neurological status between the group with DTI, navigation MRI and IOM and the group without at least one of the aforementioned measures, the difference was not statistically significant (p=0.294). The extent of resection and PLIC involvement were not related to postoperative neurological status changes.

**Histopathological findings**
The pathological diagnoses of the 37 patients were as follows: ten patients had glioblastoma, IDH-wildtype (GBL); 6 patients had anaplastic astrocytoma, IDH-wildtype (AA); 6 patients had pilocytic astrocytoma (PA); 6 patients had diffuse midline glioma, H3 K27M-mutant (DMG); 4 patients had CNS-embryonal tumor, NOS; 3 patients had diffuse astrocytoma, IDH-wildtype (DA); 1 patient had germinoma; and 1 patient had anaplastic ependymoma.

**Adjuvant therapy**
Of the 37 patients, 23 (56%) patients had both chemotherapy and radiotherapy following surgery. Three patients had only radiotherapy, one patient had only chemotherapy, and 10 patients had no adjuvant treatment.

Seven patients with GBL received chemotherapy with temozolomide (Stupp protocol) [17]. Five out of 6 patients with DMG received chemotherapy. Four of them received temozolomide, and one had POG9031 [18] for a resection. Deviated: normal or only slightly decreased fractional anisotropy (FA) with abnormal location and/or direction resulting from bulk mass displacement. Edematous: substantially decreased FA with normal location and direction (i.e., normal hues on directional color maps). Infiltrated: substantially decreased FA with abnormal hues on directional color maps. Destroyed: isotropic (or near isotropic) diffusion such that the tract cannot be identified. DTI, diffusion tensor imaging; PLIC, posterior limb of internal capsule; NA, not applicable.

| No. | Normal thalamus displacement | PLIC involve type | PLIC displacement | Surgical approach |
|-----|------------------------------|------------------|------------------|------------------|
| 1   | Lateral                      | Deviated         | Lateral          | Transcallosal    |
| 2   | Posterolateral               | Edematous        | None             | Transcallosal    |
| 3   | Anterior                     | Deviated         | Anterolateral    | Trasparietal     |
| 4   | Anteromedial                 | Deviated         | Anteromedial     | Transtemporal    |
| 5   | Posterior                    | Destroyed        | NA               | Transfrontal     |
| 6   | Inferolateral                | Deviated         | Anterolateral    | Trasparietal     |
| 7   | Inferolateral                | Deviated         | Anterolateral    | Trasparietal     |
| 8   | Lateral                      | Normal           | None             | Transcallosal    |
| 9   | Anteromedial                 | Deviated         | Anterolateral    | Trasparietal     |
| 10  | Posterior                    | Destroyed        | NA               | Transfrontal     |
| 11  | Lateral                      | Edematous        | None             | Transcallosal    |
| 12  | No identifiable normal thalamus | Deviated       | Anterolateral    | Transfrontal     |
| 13  | Posterior                    | Infiltrated      | Anterolateral    | Transcallosal    |
| 14  | Inferoposterolateral         | Infiltrated      | Lateral          | Transcallosal    |
| 15  | No identifiable normal thalamus | Deviated       | Anterolateral    | Transcallosal    |
| 16  | No identifiable normal thalamus | Infiltrated    | Anterolateral    | Transcallosal    |
| 17  | Posterior                    | Destroyed        | NA               | Transcallosal    |

Staged tumor resections were performed in one patient (Case 6, 7) (Case 10, 17) (Case 12, 15). Deviated: normal or only slightly decreased fractional anisotropy (FA) with abnormal location and/or direction resulting from bulk mass displacement. Edematous: substantially decreased FA with normal location and direction (i.e., normal hues on directional color maps). Infiltrated: substantially decreased FA with abnormal hues on directional color maps. Destroyed: isotropic (or near isotropic) diffusion such that the tract cannot be identified. DTI, diffusion tensor imaging; PLIC, posterior limb of internal capsule; NA, not applicable.
diagnosis of primitive neuroectodermal tumor based on the 2000 WHO Classification of Tumors of the CNS. Patients with AA received varied chemotherapy regimens (procarbazine+CCNU+vincristine; temozolomide+thalidomide; Stupp protocol). Patients with CNS-embryonal tumor, NOS also had various chemotherapy regimens (carboplatin+etoposide+ifosamide; carboplatin+vincristine+temozolomide; etoposide+cyclophosphamide).

**Treatment outcomes**

The mean PFS was 87.2±38.0 months. The mean PFS was 7.7±6.5 months for GBL; 11.1±7.5 months in AA; 7.0±5.8 months for DMG; 3.5±4.3 month for CNS-embryonal tumor, NOS; 122.0±86.5 months for DA; and 187.5±68.5 months for PA. The 5-year PFS was 37%. The mean OS was 90.7±36.1 months. The mean OS was 14.5±5.4 months for GBL; 23.4±4.6 months for AA; 23.8±8.9 months for DMG; 10.3±7.3 months for CNS-embryonal tumor, NOS; 122.3±86.0 months for DA; and 190.8±62.4 months for PA. The 5-year OS was 47% (Fig. 2).

In 9 patients with histopathologically proven low-grade tumor (PA, DA), the mean PFS was 200.0 months, and the mean
OS was 179.1 months. In 27 patients with high-grade tumors excluding germinoma (GBL; AA; DMG; CNS-embryonal tumor, NOS; anaplastic ependymoma), the mean PFS was 8.6 months, and the mean OS was 18.2 months. The difference between both PFS and OS between low-grade and high-grade tumors was statistically significant (p<0.001, p=0.002) (Table 3). Nineteen patients with GTR/STR had a mean PFS of 108.0 months and a mean OS of 123.8 months, while 18 patients with PR/biopsy had a mean PFS of 53.2 months and a mean OS of 46.7 months. The difference of the mean OS between these two groups was statistically significant (p=0.047). However, there was no difference in the mean PFS between the two groups (p=0.068). Ten patients without adjuvant therapy had a mean PFS of 180.0 months and a mean OS of 159.0 months, while 27 patients with adjuvant therapy had mean PFS of 43.2 months and mean OS of 48.6 months. The difference of mean OS between these two group was not statistically significant (p=0.059). However, there was significant difference of mean PFS between two groups (p=0.016) (Fig. 2).

We also divided the patients into two groups according to various factors such as age (≥10 years, <10 years), duration of symptoms (≥4 weeks, <4 weeks) and laterality (unilateral, bilateral). None of these factors were statistically significant in terms of differences of the mean PFS or mean OS.

### Table 3. Relevant prognostic factors to the mean PFS and mean OS

| Prognostic factor  | n   | Mean PFS (months) | p-value | Mean OS (months) | p-value |
|--------------------|-----|-------------------|---------|------------------|---------|
| Histology          |     |                   |         |                  |         |
| Low grade          | 9   | 200.0             | <0.001  | 179.1            | 0.002   |
| High grade         | 27  | 8.6               |         | 18.2             |         |
| Extent of resection|     |                   |         |                  |         |
| GTR/STR            | 19  | 108.0             | 0.068   | 123.8            | 0.047   |
| PR/biopsy          | 18  | 53.2              |         | 46.7             |         |
| Age at diagnosis   |     |                   |         |                  |         |
| ≥10 yrs            | 18  | 32.1              |         | 44.0             |         |
| <10 yrs            | 19  | 102.7             |         | 97.7             |         |
| Duration of presenting symptom |     |                   |         |                  |         |
| ≥4 wks             | 16  | 64.7              | 0.878   | 89.2             | 0.245   |
| <4 wks             | 21  | 94.1              |         | 74.3             |         |
| Laterality         |     |                   |         |                  |         |
| Unilateral         | 31  | 83.7              | 0.956   | 87.8             | 0.472   |
| Bilateral          | 6   | 87.5              |         | 73.5             |         |
| Adjuvant therapy   |     |                   |         |                  |         |
| Done               | 27  | 43.2              | 0.016   | 48.6             | 0.059   |
| No                 | 10  | 180.0             |         | 159.0            |         |

PFS, progression free survival; OS, overall survival; GTR, gross total resection; STR, subtotal resection; PA, partial resection.
DISCUSSION

There has been some controversy regarding surgical removal of thalamic tumors because of uncertain outcomes and operative morbidities. Previously, Bernstein et al. [19] and Bekes et al. [20] recommended biopsy or PR with adjuvant treatment. As surgical techniques improved, Cuccia and Monges [2] stated that surgical resection of thalamic tumors must be done regardless of tumor grade. Recent studies also found that GTR or STR improved survival of patients with thalamic tumors [5, 11,12]. In our study, GTR or STR of tumor proved to be a statistically significant factor for OS. Especially in low-grade tumors, it appears that radical tumor removal is much more important for survival. In the present study, GTR or STR was performed in 6 of 9 patients with low-grade tumors, and all 6 patients have survived to date. For high-grade tumors, there was no statistically significant difference in PFS and OS between the GTR/STR group and the PR/biopsy group. Nevertheless, surgical resection of tumor can also be meaningful in high-grade tumor because it can stabilize the patient’s status during adjuvant treatment by relieving increased intracranial pressure and mass effect. Furthermore, it can decrease target volume of radiotherapy. Tumor grade was the most statistically significant factor related to differences in both PFS and OS, as also reported in other studies [4,5,7,11,12,16]. Interestingly, adjuvant therapy was also a statistically significant factor for difference in PFS. This probably reflected the fact that patients with high-grade tumors were more likely to have adjuvant therapy than were patients with low-grade tumors. Unlike other reported studies [5,7,12], symptom duration and laterality proved to be irrelevant to both PFS and OS in the present study.

Unless the tumor has clear margins with normal brain tissues, radical resection of thalamic tumor carries too much risks of postoperative morbidity even to an experienced surgeon. But with advancements in imaging technologies and IOM, maximal surgical removal of thalamic tumors can be achieved with acceptable morbidity. Twenty-seven tumor resections were done for 23 patients in the present study. Staged operation was done in 4 patients, and one of them was operated on emergently because of tumor bleeding. In 27 tumor resection cases, GTR or STR were performed in 21 (78%), a higher percentage than reported in other series [5,7,11,12], and neuro-

![Fig. 3. Demonstration of planning of surgical approach via preoperative DTI. Coronal MRI (A) and DTI (B) show left thalamic tumor with anteromedially displaced thalamus and laterally deviated PLIC. The transparietal approach was adopted, and gross total resection was performed (C). Coronal MRI (D) and DTI (E) show a right thalamic tumor with anteromedially displaced thalamus and anteromedially deviated PLIC. Tumor was radically removed via a transtemporal approach (F). DTI, diffusion tensor imaging; PLIC, posterior limb of internal capsule.](image-url)
logical status worsened in only 5 cases (19%), similar to results from recent studies [5,16,21]. In addition, there was a statistically significant difference in the extent of resection between the group that employed DTI, neuro-navigation and IOM and the group that did not employ at least one of the aforementioned measures. Nevertheless, there was no statistically significant difference in postoperative neurological status between the two groups. The lack of difference in morbidity may be attributed to a more conservative surgical approach employed to minimize neurological deficits in the latter group. This is also reflected in the difference in the extent of resection, because extent of tumor resection could be maximized to the where crucial structures were not injured with application of these aforementioned technologies.

In planning a surgical approach, DTI has been introduced in several reports [10,16,22]. Using DTI, we analyzed exact location of the tumors, displacement of the thalamus and PLIC and then planned the appropriate surgical approach without invading either the thalamus or the PLIC [16,22]. We favor the anterior interhemispheral transcrallosal approach when this approach does not invade any eloquent structure such as the thalamus or the PLIC. Evaluation by DTI was done in 17 tumor resection cases, and about half of the surgeries (n=9) were performed via the interhemispheral transcrallosal approach. In cases of anterior or medial displacement of the thalamus, we choose other transcortical approaches such as the transpa- rietal or transtemporal approach, according to deviation of the PLIC. In case of posterior displacement of thalamus with destroyed PLIC, we choose the transfrontal approach. Following this principle, 8 surgeries were performed via the transcortical approach (Fig. 3). But one must be cautious about application of DTI in planning surgical approach because DTI has some limitations. First, DTI is dependent on operators which leads to difficult in interpretations and standardization [23]. And DTI is low resolution image that shows averaging effects of multiple crossing fibers in a voxel. Also, there is not established result that whether resection of fiber that seems to be infiltrated or destroyed by tumor in DTI will cause permanent neurological deficit [24]. This may reflected in the our result that there is no difference in extent of tumor resection between group with DTI and group without DTI.

Before 2016, the patients in this study were diagnosed and treated based on previous WHO Classification of Tumors of CNS. In the present study, we reviewed all pathologic specimens and rediagnosed them based on the 2016 WHO Classification of Tumors of the CNS. Therefore, it would be necessary to conduct further studies that include patients who were diagnosed and treated after 2016.

In conclusion, maximal surgical resection can be achieved with acceptable morbidity by employing DTI, navigation MRI and IOM. Maximal tumor resection should be the initial therapeutic consideration for the treatment of thalamic tumors, especially low-grade tumors.

**Conflicts of Interest**

The authors have no financial conflicts of interest.

**Acknowledgments**

This work (2017R1A2B3008422) was supported by the Mid-career Researcher Program through an NRF grant funded by the Korea government (Ministry of Science and ICT).

**REFERENCES**

1. Colosimo C, di Lella GM, Tartaglione T, Riccardi R. Neuroimaging of thalamic tumors in children. Childs Nerv Syst 2002;18:426-39.
2. Cuccia V, Monges J. Thalamic tumors in children. Childs Nerv Syst 1997;13:514-20.
3. Di Rocco C, Iannelli A. Bilateral thalamic tumors in children. Childs Nerv Syst 2002;18:480-4.
4. Fernandez C, Maues de Paula A, Colin C, et al. Thalamic gliomas in children: an extensive clinical, neuroradiological and pathological study of 14 cases. Childs Nerv Syst 2006;22:1603-10.
5. Puget S, Crimmings DW, Garnett MR, et al. Thalamic tumors in children: a reappraisal. J Neurosurg 2007;106(5 Suppl):354-62.
6. Jeelani O, Dirks P. Thalamic tumors. In: Richard Winn H, editor. Youmans and Winn neurological surgery. 7th ed. Elsevier; 2017. Ch.208
7. Bilginer B, Narin F, İşkay I, Oğuz KK, Soylmezoglu F, Akanal N. Thalamic tumors in children. Childs Nerv Syst 2014;30:1493-8.
8. Zinn Po, Colen RR, Kasper EM, Burkhardt JK. Extent of resection and radiotherapy in GBM: A 1973 to 2007 surveillance, epidemiology and end results analysis of 21,783 patients. Int J Oncol 2013;42:929-34.
9. Steiger HJ, Götz C, Schmid-Elsaesser R, Stummer W. Thalamic astrocytomas: surgical anatomy and results of a pilot series using maximum microsurgical removal. Acta Neurochir (Wien) 2000;142:1327-36.
10. Kis D, Maté A, Kincses ZT, Vörös E, Barzó P. The role of probabilistic tractography in the surgical treatment of thalamic gliomas. Neurosurgery 2014;10 Suppl 2:262-72.
11. Kramm CM, Butenhoff S, Rausch U, et al. Thalamic high-grade gliomas in children: a distinct clinical subset? Neuro Oncol 2011;13:680-9.
12. Steinbok P, Gopalakrishnan CV, Hengel AR, et al. Pediatric thalamic tumors in the MRI era: a Canadian perspective. Childs Nerv Syst 2016;32:269-80.
13. Buckner J. Factors influencing survival in high-grade gliomas. Semin Oncol 2003;30(6 Suppl 19):10-4.
14. Simpson JR, Horton J, Scott C, et al. Influence of location and extent of surgical resection on survival of patients with glioblastoma multiforme: results of three consecutive Radiation Therapy Oncology Group (RTOG) clinical trials. Int J Radiat Oncol Biol Phys 1993;26:239-44.
15. Louis DN, Perry A, Reifenberger G, et al. The 2016 World Health Organisation Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol 2016;131:803-20.
16. Sai Kiran NA, Thakar S, Dadlani R, et al. Surgical management of thalamic gliomas: case selection, technical considerations, and review of literature. Neurosurg Rev 2013;36:383-93.
17. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005;352:987-96.
18. Tarbell NJ, Friedman H, Polkington WR, et al. High-risk medulloblastoma: a pediatric oncology group randomized trial of chemotherapy before or after radiation therapy (POG 9031). J Clin Oncol 2013;31:2936-41.
19. Bernstein M, Hoffman HJ, Halliday WC, Hendrick EB, Humphreys RP. Thalamic tumors in children. Long-term follow-up and treatment
guidelines. J Neurosurg 1984;61:649-56.
20. Bek JW, Bouma GI, Journée HL. Tumours of the thalamic region. A retrospective study of 27 cases. Acta Neurochir (Wien) 1987;85:125-7.
21. Cinalli G, Aguirre DT, Mirone G, et al. Surgical treatment of thalamic tumors in children. J Neurosurg Pediatr 2018;21:247-57.
22. Moshel YA, Elliott RE, Monoky DJ, Wisoff JH. Role of diffusion tensor imaging in resection of thalamic juvenile pilocytic astrocytoma. J Neurosurg Pediatr 2009;4:495-505.
23. Tournier JD, Calamante F, King MD, Gadian DG, Connelly A. Limitations and requirements of diffusion tensor fiber tracking: an assessment using simulations. Magn Reson Med 2002;47:701-8.
24. Bizzi A. Presurgical mapping of verbal language in brain tumors with functional MR imaging and MR tractography. In: Pia Sundgren M, editor. Advanced imaging techniques in brain tumors. Elsevier;2009. p.573-96.